Boston Scientific shares plunge 53% amid lowered growth forecasts and product challenges

Boston Scientific's stock has fallen about 53% over the past year due to lowered full-year 2026 growth guidance, slowing WATCHMAN device sales, loss of electrophysiology market share, and mixed clinical trial results from CHAMPION-AF. The company now expects 6.5-8.0% organic revenue growth and $3.34-$3.41 earnings per share in FY26, down from previous targets, with management also reducing long-term growth expectations below 10%. Despite this, Boston Scientific trades at a notable discount compared to peers, reflecting concerns already priced in. Analysts suggest buying on weakness as upcoming July earnings could indicate a recovery point.